In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel

Ann Intern Med. 2020 Oct 20;173(8):JC44. doi: 10.7326/ACPJ202010200-044.

Abstract

Navarese EP, Khan SU, Kolodziejczak M, et al. Comparative efficacy and safety of oral P2Y 12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150-60. 32468837.

Publication types

  • Comment

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • Clopidogrel / adverse effects
  • Humans
  • Network Meta-Analysis
  • Prasugrel Hydrochloride / adverse effects
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Randomized Controlled Trials as Topic
  • Ticagrelor / adverse effects

Substances

  • Purinergic P2Y Receptor Antagonists
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticagrelor